CalciMedica, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $15.2M | $14.5M | $15.9M | $8.3M | $18.9M |
| Operating expenses | $23.1M | $24.2M | $38.1M | $14.2M | $35.9M |
| Operating income | -$23.1M | -$24.2M | -$38.1M | -$14.2M | -$35.9M |
| Interest expense | $1.4M | $0 | — | — | — |
| Pretax income | -$29.6M | -$13.7M | — | — | — |
| Income tax expense | $0 | $0 | $1,000 | $1,000 | — |
| Net income | -$29.6M | -$13.7M | -$34.4M | -$7.8M | -$35.8M |
| Balance Sheet | |||||
| Cash and equivalents | $11.5M | $7.9M | $5.5M | $1.3M | $13.4M |
| Current assets | $13.5M | $19.7M | $11.6M | $1.7M | $67.1M |
| Total assets | $13.6M | $19.8M | $12.2M | $3.3M | $69.1M |
| Current liabilities | $3.8M | $3.7M | $4.0M | $4.8M | $4.1M |
| Total liabilities | $20.2M | $5.4M | $4.0M | $12.6M | $4.1M |
| Stockholders' equity | -$6.6M | $14.4M | $8.2M | -$71.3M | -$64.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$21.2M | -$21.1M | -$25.7M | -$11.8M | -$31.5M |
| Depreciation and amortization | $46,000 | $58,000 | $58,000 | $52,000 | $519,000 |
| Stock-based compensation | $3.0M | $2.3M | $12.0M | $1.8M | $5.4M |
| Capital expenditure | $28,000 | $8,000 | $78,000 | $4,000 | $488,000 |
| Free cash flow | -$21.2M | -$21.2M | -$25.8M | -$11.8M | -$32.0M |
| Impairments | — | — | $0 | $1.6M | $0 |
Shares outstanding 15.8M
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.